Loading...
Market
When will RGX-202 be launched in the market?
2
Resolution / Starting Odds
Before 2025 • 25%
In 2025 • 25%
In 2026 • 25%
After 2026 • 25%
Regenxbio's official announcements or market reports
Story
Regenxbio's RGX-202 Gene Therapy Shows Positive Results, FDA Approval Pathway Available
Nov 18, 2024, 12:34 PM
Regenxbio has reported promising results from its experimental gene therapy, RGX-202, for treating boys with Duchenne muscular dystrophy. The company presented clinical evidence showing improved muscle function in patients following the treatment. Regenxbio's CEO, Curran Simpson, indicated in an interview with STAT on Sunday that the FDA has communicated that the accelerated approval pathway remains available for this therapy. The positive data from a small trial is expected to support Regenxbio's pursuit of regulatory approval.
View original story
Similar markets
Approval • 33%
Rejection • 33%
Request for more data • 34%
Yes • 50%
No • 50%
First half of 2025 • 25%
Second half of 2025 • 25%
2026 • 25%
2027 or later • 25%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%
Yes • 50%
No • 50%
Breakthrough Therapy • 25%
Fast Track • 25%
Orphan Drug • 25%
None • 25%
